HALO ▼ -10.0% - Halozyme Therapeutics, Inc.
$HALO HALO - U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
06-NOV-2026 09:58 AM ET
Share this post
More filings for $HALO
HALO ▼ -12.4% - Halozyme Therapeutics, Inc.Nov 6, 2026HALO ▼ -12.3% - Halozyme Therapeutics, Inc.Nov 5, 2026HALO ▲ +0.3% - Halozyme Therapeutics, Inc.Oct 22, 2026HALO ▲ +1.6% - Halozyme Therapeutics, Inc.Oct 6, 2026HALO ▼ -1.1% - Halozyme Therapeutics, Inc.Sep 30, 2026HALO ▲ +1.2% - Halozyme Therapeutics, Inc.Sep 18, 2026
View full $HALO filing history →💬 Comments
Loading comments…
Leave a comment